ADPT
$67.74
Adaptive Biotechnologies
$.73
1.09%
ADPT
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.30)
Revenue:  $27.11 Mil
Wednesday
Feb 24
4:10 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ADPT reports earnings?
Beat
Meet
Miss

Where is ADPT's stock price going from here?
Up
Flat
Down
Stock chart of ADPT
Analysts
Summary of analysts' recommendations for ADPT
Score
Grade
Pivots
Resistance
$71.20
$69.68
$68.71

$67.19

Support
$66.22
$64.70
$63.73
Tweet
Growth
Description
Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington.
Peers
Magellan Health Services